Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
HU-308, a synthetic cannabinoid has demonstrated in vivo anti-osteoporotic efficacy of agonist highly specific for CB2 that concomitantly restrains bone resorption and stimulates bone formation. HU-308 has no psychotropic or anti-annorexigenic... More
Novel radiolabeled compounds for radioimaging (e.g., positron emitting tomography (PET), Computed Tomography (CT), PET/CT and Single Photon Emission Tomography (SPECT)) and/or radiotherapy. These radiolabeled compounds are designed for use in a... More
The advantage of this drug delivery system is the ability to directly target specific skeletal sites of disease, while also being able to administer the lowest, clinically effective dose possible, thereby lowering the potential for harmful side effec More
A simple blood test that confirms the CB receptor variant (normal or mutated) can serve as the basis for the development of novel diagnostic modalities to determine predisposition to osteoporosis and improve the diagnosis in individuals suspected of... More
All rights reserved. Terms and Conditions | Contact us
